Physician

Emidio Michael Novembre, DO

According to 2025 Medicare claims, Emidio Novembre, DO (NPI: 1750308664) practices interventional pain management (ipm), with the plurality of this provider's patient population coming from Wilkes, NC. This provider's primary affiliated billing organization is REVIVAL PAIN MANAGEMENT INC (NPI: 1801813712; TIN: 364538583) and primary practice location at 28621-2105. Novembre is affiliated with the CHESS Value, LLC (ACO ID: A3391), participating under the MSSP model.

Novembre's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 244 traditional Medicare patients, billed 10,058 HCPCS/CPT codes, and received $206,454 in Medicare payments. The top billing code was G0481 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). Part D data shows 7,236 prescription claims across 627 beneficiaries totaling $287,638 in drug costs, led by Linzess (Linaclotide). Open Payments data shows 10 records totaling $196. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $67,186 to $206,454. Similarly, Part D prescription costs have moved sharply higher in recent years, from $98,564 to $287,638. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	242	1,238	$67,186
2016	226	889	$46,486
2017	182	766	$40,983
2018	194	692	$40,984
2019	185	615	$40,342
2020	214	627	$33,852
2021	339	1,104	$82,870
2022	195	1,174	$93,774
2023	269	1,984	$180,560
2024	244	10,058	$206,454

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	268	1,076	$98,564
2016	273	1,350	$111,941
2017	202	950	$69,603
2018	210	933	$75,199
2019	188	690	$49,249
2020	156	586	$32,445
2021	336	1,206	$67,040
2022	382	1,687	$85,356
2023	699	5,170	$305,379
2024	627	7,236	$287,638

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	134	276	$151
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	142	509	$74
80307	Testing for presence of drug, by chemistry analyzers	169	381	$59
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	147	387	$52
J1010	Injection, methylprednisolone acetate, 1 mg	86	7,765	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Linzess	Linaclotide	80	2,460	$43,548
Rexulti	Brexpiprazole	25	744	$36,880
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	224	6,511	$30,504
Oxycodone Hcl	Oxycodone Hcl	1,203	35,053	$25,514
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	739	21,163	$23,773

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$196	Forte Bio-Pharma LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

Interventional Pain Management (IPM) providers
Providers within practice ZIP code 28621-2105
Providers whose plurality patient county is Wilkes, NC
Providers in North Carolina whose primary affiliated billing organization is REVIVAL PAIN MANAGEMENT INC
Providers in North Carolina affiliated with CHESS Value, LLC (MSSP)

FAQ

What Medicare data is available for Emidio Michael Novembre, DO?

Tedicare shows public-source Medicare data for Emidio Michael Novembre, DO (NPI 1750308664), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Emidio Michael Novembre, DO have ACO affiliation data?

Emidio Michael Novembre, DO is shown with ACO affiliation data for CHESS Value, LLC (MSSP, ACO ID A3391).

What billing organization is linked to Emidio Michael Novembre, DO?

Emidio Michael Novembre, DO is linked to REVIVAL PAIN MANAGEMENT INC (billing NPI 1801813712) in the available physician profile data.

Does Emidio Michael Novembre, DO have Open Payments data?

Emidio Michael Novembre, DO has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.